Antithrombotic treatment pattern in newly diagnosed atrial fibrillation patients and 2-year follow-up results for dabigatran-treated patients in the Africa/Middle-East Region: Phase II results from the GLORIA-AF registry program

dc.contributor.authorAzar, Rabih R.
dc.contributor.authorRagy, Hany
dc.contributor.authorKozan, Omer
dc.contributor.authorEl Khuri, Maurice
dc.contributor.authorBazergani, Nooshin
dc.contributor.authorMarler, Sabrina
dc.contributor.authorTeutsch, Christine
dc.contributor.authorIbrahim, Mohammed
dc.contributor.authorLip, Gregory Y. H.
dc.contributor.authorHuisman, Menno
dc.contributor.pubmedID33912651en_US
dc.contributor.researcherIDABC-9349-2021en_US
dc.date.accessioned2022-08-31T12:00:43Z
dc.date.available2022-08-31T12:00:43Z
dc.date.issued2021
dc.description.abstractBackground: Data on the epidemiology and treatment of atrial fibrillation in the Africa/Middle East region are limited, and the use of novel oral anticoagulants and their effectiveness in real-world clinical practice has not been evaluated. Methods and Results: This study used prospectively collected data from the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation (GLORIA-AF) to describe anticoagulant use and outcomes in Africa and the Middle East. Baseline characteristics of patients newly diagnosed with nonvalvular atrial fibrillation from Lebanon (242 patients, 40.3%), Saudi Arabia (236 patients, 39.3%), United Arab Emirates (87 patients, 14.5%), and South Africa (35 patients, 5.8%) were described, and clinical outcomes were investigated for all patients in this region who received dabigatran. In newly diagnosed patients (having a diagnosis within the last three months) with nonvalvular atrial fibrillation in Africa and the Middle East, the observed uptake of non-vitamin K oral anticoagulants was high in the first years following their availability; dabigatran was the most commonly used antithrombotic agent (314/600 patients), and only 1.5% of patients did not receive any antithrombotic therapy. Use of dabigatran was associated with a high persistence rate (>88% at 24 months) and low incidence rates of stroke, myocardial infarction, major bleeding, and all-cause mortality after 2 years of follow-up. Conclusions: Data from GLORIA-AF reveal a change in the landscape for stroke prevention in the AME region, and the results were consistent with those observed in the global GLORIA-AF registry, as well as those of randomized clinical trials. (C) 2021 The Authors. Published by Elsevier B.V.en_US
dc.identifier.eissn2352-9067en_US
dc.identifier.scopus2-s2.0-85103954002en_US
dc.identifier.urihttps://www.clinicalkey.com/#!/content/playContent/1-s2.0-S2352906721000518?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2352906721000518%3Fshowall%3Dtrue&referrer=https:%2F%2Fwww.webofscience.com%2F
dc.identifier.urihttp://hdl.handle.net/11727/7476
dc.identifier.volume34en_US
dc.identifier.wos000667480400021en_US
dc.language.isoengen_US
dc.relation.isversionof10.1016/j.ijcha.2021.100763en_US
dc.relation.journalIJC HEART & VASCULATUREen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnticoagulanten_US
dc.subjectAtrial fibrillationen_US
dc.subjectNOACsen_US
dc.titleAntithrombotic treatment pattern in newly diagnosed atrial fibrillation patients and 2-year follow-up results for dabigatran-treated patients in the Africa/Middle-East Region: Phase II results from the GLORIA-AF registry programen_US
dc.typearticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
1-s2.0-S2352906721000518.pdf
Size:
318.59 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: